يعرض 1,121 - 1,140 نتائج من 5,204 نتيجة بحث عن '(( significant decrease decrease ) OR ( significance ((levels decrease) OR (levels increased)) ))~', وقت الاستعلام: 0.53s تنقيح النتائج
  1. 1121
  2. 1122
  3. 1123
  4. 1124
  5. 1125
  6. 1126
  7. 1127
  8. 1128

    Crossing Barriers<i>: In Vitro</i> Cancer Model for Studying Monocyte Migration across Endothelial Barriers حسب Mandeep K. Marway (21734690)

    منشور في 2025
    "…Inflammatory cytokines, such as granulocyte–macrophage colony-stimulating factor (GM-CSF), interleukin-6 (IL-6), interleukin-10 (IL-10), and interleukin-1β (IL-1β) secretion levels increased, while tumor necrosis factor α (TNF-α) and interleukin-12p40 (IL-12p40) levels decreased and monocyte chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8) levels remained unchanged in the presence of the EC barrier and spheroids, confirming the importance of the EC barrier for monocyte activation and migration. …"
  9. 1129

    Crossing Barriers<i>: In Vitro</i> Cancer Model for Studying Monocyte Migration across Endothelial Barriers حسب Mandeep K. Marway (21734690)

    منشور في 2025
    "…Inflammatory cytokines, such as granulocyte–macrophage colony-stimulating factor (GM-CSF), interleukin-6 (IL-6), interleukin-10 (IL-10), and interleukin-1β (IL-1β) secretion levels increased, while tumor necrosis factor α (TNF-α) and interleukin-12p40 (IL-12p40) levels decreased and monocyte chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8) levels remained unchanged in the presence of the EC barrier and spheroids, confirming the importance of the EC barrier for monocyte activation and migration. …"
  10. 1130

    Crossing Barriers<i>: In Vitro</i> Cancer Model for Studying Monocyte Migration across Endothelial Barriers حسب Mandeep K. Marway (21734690)

    منشور في 2025
    "…Inflammatory cytokines, such as granulocyte–macrophage colony-stimulating factor (GM-CSF), interleukin-6 (IL-6), interleukin-10 (IL-10), and interleukin-1β (IL-1β) secretion levels increased, while tumor necrosis factor α (TNF-α) and interleukin-12p40 (IL-12p40) levels decreased and monocyte chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8) levels remained unchanged in the presence of the EC barrier and spheroids, confirming the importance of the EC barrier for monocyte activation and migration. …"
  11. 1131
  12. 1132
  13. 1133

    The Laboratory Animal Flow Diagram. حسب Xueqin lu (22250795)

    منشور في 2025
    "…This unique design enables both THR-β activation and targeted delivery to hepatocytes, which significantly reduces the risk of adverse effects related to increased systemic thyroid hormone activity. …"
  14. 1134

    <sup>1</sup>H NMR spectra for kylo-0603. حسب Xueqin lu (22250795)

    منشور في 2025
    "…This unique design enables both THR-β activation and targeted delivery to hepatocytes, which significantly reduces the risk of adverse effects related to increased systemic thyroid hormone activity. …"
  15. 1135

    <sup>13</sup>C NMR spectra for Kylo-0603. حسب Xueqin lu (22250795)

    منشور في 2025
    "…This unique design enables both THR-β activation and targeted delivery to hepatocytes, which significantly reduces the risk of adverse effects related to increased systemic thyroid hormone activity. …"
  16. 1136

    The structures of T3 and Kylo-0603. حسب Xueqin lu (22250795)

    منشور في 2025
    "…This unique design enables both THR-β activation and targeted delivery to hepatocytes, which significantly reduces the risk of adverse effects related to increased systemic thyroid hormone activity. …"
  17. 1137

    Synthesis process of Kylo-0603. حسب Xueqin lu (22250795)

    منشور في 2025
    "…This unique design enables both THR-β activation and targeted delivery to hepatocytes, which significantly reduces the risk of adverse effects related to increased systemic thyroid hormone activity. …"
  18. 1138

    ESI-HRMS spectra for Kylo-0603. حسب Xueqin lu (22250795)

    منشور في 2025
    "…This unique design enables both THR-β activation and targeted delivery to hepatocytes, which significantly reduces the risk of adverse effects related to increased systemic thyroid hormone activity. …"
  19. 1139
  20. 1140